Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the publication of data that further validate the potential of its mass cytometry technologies, CyTOF® and Imaging Mass Cytometry™ (IMC™), to provide new approaches to evaluating cancer therapies in animal models using human tumor xenografts, potentially identifying which patients are most likely to benefit from specific targeted cancer therapies.

The research was led by scientists at the Cancer Research UK (CRUK) Cambridge Institute at the University of Cambridge in collaboration with the Imaging and Molecular Annotation of Xenografts and Tumors (IMAXT) Cancer Grand Challenges Consortium, and the data have been published online in Nature Communications. This work was funded by Cancer Grand Challenges, AstraZeneca, a European Research Council Advanced Grant and the EU Marie Sklodowska-Curie Research program.

Researchers developed a panel of 33 antibodies designed to detect and differentiate human tumor cells from the surrounding mouse cells and to detect activation of cancer-related signaling pathways as well as markers of cell death (including programmed cell death). The breast cancer mass cytometry (BCMC) antibody panel was validated in a variety of well-characterized cell lines and then used to evaluate 53 human breast cancer xenograft samples capturing the diversity of breast cancers observed in patients, as previously shown and published in Cell (Bruna et al., 2016).

Click the button below to read the entire Press Release:

Continue Reading The Press Release